Eaton Vance Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Eaton Vance Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-65	Closed	–	–	2860
2021 Q3	$0	Hold	65	–	–	﹤0.01%	2490
2021 Q2	$1K	Buy	+65	New	+$743	﹤0.01%	2768

Other funds holding ORMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Eaton Vance Management's ORMP Position: Q4 2021 in Review

Eaton Vance Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 65 shares.

Eaton Vance Management first reported a position in ORMP in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

Eaton Vance Management reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Eaton Vance Management sold 65 Oramed Pharmaceuticals shares in Q4 2021.
Eaton Vance Management first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 2 quarters.
Eaton Vance Management's Oramed Pharmaceuticals position peaked at $1K in Q2 2021.
116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Eaton Vance Management's 13F filing for Q4 2021, filed 14 Feb 2022.